AI Article Synopsis

  • Eyelid spasms in patients with hemifacial spasm (HFS) may lead to elevated intraocular pressure (IOP), which complicates accurate measurement using traditional methods like the Goldmann applanation tonometer (GAT).
  • This study evaluated IOP using the Diaton® transpalpebral tonometer in 27 HFS patients before and after botulinum toxin type A (BTX-A) treatment and compared these results to GAT measurements.
  • The results indicated a significant reduction in IOP on the affected side after BTX-A treatment, showing that eyelid spasms can increase IOP, but no significant differences were found between Diaton® and GAT readings post-treatment.

Article Abstract

Purpose: Eyelid spasms might be associated with elevated intraocular pressure (IOP) in hemifacial spasm (HFS) patients. IOP assessment using a Goldmann applanation tonometer (GAT) is often compromised by eyelid spasms. This study aimed to assess the effect of HFS on IOP measurements using the transpalpebral tonometer Diaton® before and after treatment with botulinum toxin type A (BTX-A) and compared Diaton® and GAT measurements after treatment with BTX-A.

Methods: IOP measurements were obtained with Diaton® in 27 patients with moderate-to-severe HFS before and after treatment with BTX-A. After treatment, the IOP was also measured using GAT and the results were compared with the ones measured with a Diaton®. The patients underwent automated perimetry, OCT, and pachymetry for screening to glaucoma.

Results: Mean IOP with Diaton® was 11 ± 3.42 mmHg before treatment in the affected eye and 9 ± 2.98 mmHg in the contralateral eye. This difference was statistically significant (P = 0.012). However, after treatment with BTX-A, no interocular difference was found in IOP obtained with Diaton® (P = 0.204) or GAT (P = 0.971). Comparison between GAT and Diaton® measurements showed no significant differences after BTX-A treatment between the affected (P = 0.212) and contralateral eye (P = 0.971).

Conclusions: A significant reduction in IOP measurements on the affected side of HFS patients was observed after treatment with BTX-A, demonstrating that eyelid spasms may increase the IOP. No significant difference was observed between Diaton® and GAT measurements after the application of BTX-A. No differences were found in automated perimetry, OCT, and CCT when comparing affected eyes with contralateral eyes.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10792-023-02898-6DOI Listing

Publication Analysis

Top Keywords

eyelid spasms
16
iop measurements
12
treatment btx-a
12
treatment
9
iop
9
botulinum toxin
8
intraocular pressure
8
transpalpebral tonometer
8
hfs patients
8
diaton®
8

Similar Publications

Engaging dystonia networks with subthalamic stimulation.

Proc Natl Acad Sci U S A

January 2025

Center for Brain Circuit Therapeutics, Department of Neurology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115.

Deep brain stimulation is an efficacious treatment for dystonia. While the internal pallidum serves as the primary target, recently, stimulation of the subthalamic nucleus (STN) has been investigated. However, optimal targeting within this structure and its surroundings have not been studied in depth.

View Article and Find Full Text PDF

Background: Dystonia may respond to VMAT2 inhibition.

Objectives: Providing pilot data on the safety, tolerability, and efficacy of deutetrabenazine in non dopa-responsive dystonia.

Methods: Deutetrabenazine was titrated by adults with isolated dystonia.

View Article and Find Full Text PDF

Background: Acanthamoeba keratitis (AK) is the most challenging corneal infection to treat, with conventional therapies often proving ineffective. While photoactivated chromophore for keratitis-corneal cross-linking (PACK-CXL) with riboflavin/UV-A has shown success in treating bacterial and fungal keratitis, and PACK-CXL with rose bengal/green light has demonstrated promise in fungal keratitis, neither approach has been shown to effectively eradicate AK. This case study explores a novel combined same-session treatment approach using both riboflavin/UV-A and rose bengal/green light in a single procedure.

View Article and Find Full Text PDF

Factor analysis and clustering of motor and psychiatric dimensions in idiopathic blepharospasm.

Parkinsonism Relat Disord

December 2024

IRCCS NEUROMED, Pozzilli, Italy; Department of Translational Biomedicine and Neuroscience, Aldo Moro University of Bari, Italy.

Introduction: Idiopathic blepharospasm is a clinically heterogeneous form of focal dystonia, also associated with psychiatric symptoms. The identification of the most relevant sets of motor and psychiatric manifestations may help better understand the specific phenomenology of the condition and delineate blepharospasm subtypes more accurately.

Methods: Patients with idiopathic blepharospasm were from the Dystonia Coalition project.

View Article and Find Full Text PDF

Botulinum neurotoxin type-A (BoNT/A), which blocks quantal acetylcholine (ACh) release at the neuromuscular junction (NMJ), has demonstrated its efficacy in the symptomatic treatment of blepharospasm. In 3.89% of patients treated for blepharospasm at Tenon Hospital, BoNT/A was no longer effective in relieving the patient's symptoms, and a partial upper myectomy of the muscle was performed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!